Solventum Co. (NYSE:SOLV) Shares Purchased by Van ECK Associates Corp

Van ECK Associates Corp raised its position in Solventum Co. (NYSE:SOLV) by 28.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 47,224 shares of the company’s stock after purchasing an additional 10,530 shares during the quarter. Van ECK Associates Corp’s holdings in Solventum were worth $3,120,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the company. Worldquant Millennium Advisors LLC raised its holdings in Solventum by 373.6% during the third quarter. Worldquant Millennium Advisors LLC now owns 47,665 shares of the company’s stock worth $3,323,000 after purchasing an additional 37,600 shares in the last quarter. Harbor Capital Advisors Inc. raised its holdings in Solventum by 24.8% during the fourth quarter. Harbor Capital Advisors Inc. now owns 46,965 shares of the company’s stock worth $3,103,000 after purchasing an additional 9,333 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in Solventum by 37.4% during the third quarter. The Manufacturers Life Insurance Company now owns 117,853 shares of the company’s stock worth $8,217,000 after purchasing an additional 32,051 shares in the last quarter. State Street Corp raised its holdings in Solventum by 3.1% during the third quarter. State Street Corp now owns 6,107,550 shares of the company’s stock worth $425,818,000 after purchasing an additional 185,938 shares in the last quarter. Finally, Forsta AP Fonden bought a new stake in Solventum during the fourth quarter worth approximately $1,876,000.

Solventum Price Performance

NYSE SOLV opened at $74.44 on Friday. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $96.05. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. The firm’s 50 day moving average price is $71.07 and its two-hundred day moving average price is $68.95.

Analyst Ratings Changes

SOLV has been the topic of several recent analyst reports. Morgan Stanley boosted their target price on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Mizuho assumed coverage on shares of Solventum in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price target on the stock. Finally, Piper Sandler lifted their price target on shares of Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, Solventum presently has a consensus rating of “Hold” and an average target price of $68.29.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.